Myanmar Pharmaceuticals and Healthcare Report Q3 2013:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Myanmar Pharmaceuticals and Healthcare Report Q3 2013 Jul 17th 2013, 00:00, by rnrmahesh BMI View: Despite its small size, Myanmar’s pharmaceutical market offers drugmakers strong revenueearning opportunities. Generic and over-the-counter drug companies in particular stand to benefit, as the population’s per capita expenditure on pharmaceuticals and healthcare remains low but set to rise. However we believe that the country remains a high-risk market as a result of political risks arising from ethnic tensions, in addition to the challenging economic framework – the result of corruption and unclear regulations. Headline Expenditure Projections •Pharmaceuticals: MMK241.2bn (US$280mn) in 2012 to MMK279.5bn (US$320mn) in 2013; +15.9% in local currency terms and 14.1% in US dollar terms. •Healthcare: … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=107782. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/myanmar-pharmaceuticals-and-healthcare-report-q3-2013-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions